Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $266M; returns 1 day -1.0%, 1 week +17.4%, 1 year -25.3%.

Contineum Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with high unmet medical need.

Groups CTNM belongs to

• Clinical Stage Biotech
• Biotechnology
• Healthcare
• Biopharmaceutical
• Clinical Stage
• Neuroscience
• CNS Disorders
• Drug Discovery
• Unmet Medical Needs
• Strategic Partnerships
• Pharmaceuticals

CTNM financial model: income statement, cash flow and balance sheet